Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data - PubMed (original) (raw)
- PMID: 4793138
Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data
R Peto et al. Biometrics. 1973 Sep.
No abstract available
Similar articles
- A qualitative discrepancy between censored data rank tests.
Prentice RL, Marek P. Prentice RL, et al. Biometrics. 1979 Dec;35(4):861-7. Biometrics. 1979. PMID: 393312 - Some statistical viewpoints in the study of carcinogenesis.
Mantel N. Mantel N. Prog Exp Tumor Res. 1969;11:431-43. doi: 10.1159/000391405. Prog Exp Tumor Res. 1969. PMID: 5769555 No abstract available. - Nonparametric estimation of the survival function when cause of death is uncertain.
Racine-Poon AH, Hoel DG. Racine-Poon AH, et al. Biometrics. 1984 Dec;40(4):1151-8. Biometrics. 1984. PMID: 6534414 - [Statistical methods in the study of carcinogenicity in animal experiments].
Maksimovich DM, Parfenov IuD. Maksimovich DM, et al. Vopr Onkol. 1990;36(3):276-85. Vopr Onkol. 1990. PMID: 2184580 Review. Russian. No abstract available. - Limitations and inconsistencies in the approaches to cancer prevention.
Tomatis L. Tomatis L. Teratog Carcinog Mutagen. 1995-1996;15(6):277-82. doi: 10.1002/(SICI)1520-6866(1996)15:6<277::AID-TCM4>3.0.CO;2-F. Teratog Carcinog Mutagen. 1995. PMID: 8732879 Review. No abstract available.
Cited by
- R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.
Sancho JM, Fernández-Alvarez R, Gual-Capllonch F, González-García E, Grande C, Gutiérrez N, Peñarrubia MJ, Batlle-López A, González-Barca E, Guinea JM, Gimeno E, Peñalver FJ, Fuertes M, Bastos M, Hernández-Rivas JÁ, Moraleda JM, García O, Sorigué M, Martin A. Sancho JM, et al. Cancer Med. 2021 Feb;10(4):1314-1326. doi: 10.1002/cam4.3730. Epub 2021 Jan 25. Cancer Med. 2021. PMID: 33492774 Free PMC article. Clinical Trial. - Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib.
Chhikara S, Sazawal S, Singh K, Chaubey R, Pati H, Tyagi S, Mahapatra M, Saxena R. Chhikara S, et al. South Asian J Cancer. 2018 Oct-Dec;7(4):258-262. doi: 10.4103/sajc.sajc_244_17. South Asian J Cancer. 2018. PMID: 30430096 Free PMC article. - Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.
Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M. Adhoute X, et al. World J Gastroenterol. 2017 Apr 14;23(14):2545-2555. doi: 10.3748/wjg.v23.i14.2545. World J Gastroenterol. 2017. PMID: 28465639 Free PMC article. - Impact of early root competition on fitness components of four semiarid species.
Reichenberger G, Pyke DA. Reichenberger G, et al. Oecologia. 1990 Dec;85(2):159-166. doi: 10.1007/BF00319397. Oecologia. 1990. PMID: 28312551 - Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial.
Rosiñol L, Oriol A, Teruel AI, de la Guía AL, Blanchard M, de la Rubia J, Granell M, Sampol M, Palomera L, González Y, Etxebeste M, Martínez-Martínez R, Hernández MT, de Arriba F, Alegre A, Cibeira M, Mateos M, Martínez-López J, Lahuerta JJ, San Miguel J, Bladé J. Rosiñol L, et al. Leukemia. 2017 Sep;31(9):1922-1927. doi: 10.1038/leu.2017.35. Epub 2017 Jan 23. Leukemia. 2017. PMID: 28111466 Clinical Trial.